Eye Disease & Ophthalmology Clinical Trials Update: Week 25, 2026

Published June 19, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Evaluation of the Impact of Oral Ivermectin on Musca Sorbens Flies, Putative Vector of Trachoma

This Phase 4 trial is exploring whether oral ivermectin can reduce the population of Musca sorbens flies, which are believed to spread trachoma, an infectious eye disease that can cause blindness. If effective, this approach could offer a new way to prevent trachoma by targeting the flies that carry the infection. The study is currently recruiting healthy volunteers in the United Kingdom to better understand how ivermectin might impact fly survival and disease transmission.

A Randomized Trial of Low-Dose Bevacizumab vs Laser for Type 1 ROP

This Phase 3 trial compares low-dose bevacizumab, an injection to block abnormal blood vessel growth, with the standard laser treatment in infants with type 1 retinopathy of prematurity (ROP). The study enrolled 16 infants across the United States and Canada and has reported results. If low-dose bevacizumab proves effective, it could provide a treatment option that may reduce side effects and improve visual outcomes for premature babies facing this serious eye condition.

A Study to Investigate Aqueous Humor and Multimodal Imaging Biomarkers in Treatment-Naïve Participants With Diabetic Macular Edema Treated With Faricimab

This Phase 2 trial tested faricimab, a new antibody treatment, in nearly 100 patients with diabetic macular edema, a common cause of vision loss in people with diabetes. The study examined eye fluid and imaging markers to better understand how faricimab works. If successful, this treatment may improve vision and reduce how often patients need injections, potentially easing the treatment burden for those managing this condition.

Biomarker of Diabetic Retinopathy

This ongoing study is investigating a new biomarker approach using blood samples to better monitor diabetic retinopathy, a complication of diabetes that affects the retina. The research aims to help doctors track blood vessel health in the eye more effectively and identify changes earlier. This could lead to more personalized care and timely treatments for adults with varying stages of diabetic retinopathy. The trial is recruiting participants in the United States.

Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

This Phase 1 trial is testing ABBV-6628, an investigational antibody injection, in adults aged 50 and older with geographic atrophy related to age-related macular degeneration. The study focuses on safety and how the drug moves through the body. If this treatment proves safe and effective, it could offer a new way to slow vision loss in this common age-related eye condition. The trial is recruiting participants in the United States and will last approximately 22 months plus follow-up.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.